Effectiveness of statins in the reduction of the risk of myocardial infarction is modified by the GNB3 C825T variant

Pharmacogenetics and Genomics

Volumn 18, Issue 7, 2008, Pages 631-636

  Peters, Bas J M ^a   Maitland Van Der Zee, Anke Hilse ^a   Stricker, Bruno H Ch ^b   Van Wieren De Wijer, Diane B M A ^a   De Boer, Anthonius ^a   Kroon, Abraham A ^c   De Leeuw, Peter W ^c   Schiffers, Paul ^d   Janssen, Rob G J H ^c   Van Duijn, Cornelia M ^b   Klungel, Olaf H ^a  

^a UTRECHT UNIVERSITY   (Netherlands)

^b ERASMUS MEDICAL CENTER   (Netherlands)

^c MAASTRICHT UNIVERSITY   (Netherlands)

^d MAASTRICHT UNIVERSITY   (Netherlands)

Author keywords

GNB3 protein; Myocardial infarction; Pharmacogenetics; Polymorphism case control study; Statin

Indexed keywords

HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; ANTIHYPERTENSIVE AGENT; G PROTEIN BETA3 SUBUNIT; G-PROTEIN BETA3 SUBUNIT; HETEROTRIMERIC GUANINE NUCLEOTIDE BINDING PROTEIN; HYPOCHOLESTEROLEMIC AGENT;

ADULT; ALLELE; ARTICLE; COMPARATIVE STUDY; CONTROLLED STUDY; DNA MODIFICATION; DRUG EFFICACY; DRUG EXPOSURE; FEMALE; GENE INTERACTION; GENETIC ASSOCIATION; GENETIC POLYMORPHISM; GENETIC VARIABILITY; HEART INFARCTION; HOSPITAL DISCHARGE; HUMAN; HYPERCHOLESTEROLEMIA; MAJOR CLINICAL STUDY; MALE; POPULATION BASED CASE CONTROL STUDY; PRIORITY JOURNAL; REGISTER; RISK REDUCTION; WILD TYPE; CASE CONTROL STUDY; DRUG RESISTANCE; GENE FREQUENCY; GENETICS; GENOTYPE; MISSENSE MUTATION; PHYSIOLOGY; RISK FACTOR; SINGLE NUCLEOTIDE POLYMORPHISM; TREATMENT OUTCOME;

ANTICHOLESTEREMIC AGENTS; ANTIHYPERTENSIVE AGENTS; CASE-CONTROL STUDIES; DRUG RESISTANCE; GENE FREQUENCY; GENOTYPE; HETEROTRIMERIC GTP-BINDING PROTEINS; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; HYPERCHOLESTEROLEMIA; MUTATION, MISSENSE; MYOCARDIAL INFARCTION; POLYMORPHISM, SINGLE NUCLEOTIDE; RISK FACTORS; TREATMENT OUTCOME;

EID: 53049095424     PISSN: 17446872     EISSN: 17446880     Source Type: Journal    
DOI: 10.1097/FPC.0b013e3283023fb2     Document Type: Article

References (40)

1. McGovern PG, Jacobs DR Jr, Shahar E, Arnett DK, Folsom AR, Blackburn H, et al. Trends in acute coronary heart disease mortality, morbidity, and medical care from 1985 through 1997: the Minnesota heart survey. Circulation 2001; 104:19-24.
2. Cheung BM, Lauder IJ, Lau CP, Kumana CR. Meta-analysis of large randomized controlled trials to evaluate the impact of statins on cardiovascular outcomes. Br J Clin Pharmacol 2004; 57:640-651.
3. Maitland-van der Zee AH, Boerwinkle E. Pharmacogenetics of response to statins: where do we stand? Curr Atheroscler Rep 2005; 7:204-208.
4. Mangravite LM, Krauss RM. Pharmacogenomics of statin response. Curr Opin Lipidol 2007; 18:409-414.
5. Siffert W, Rosskopf D, Siffert G, Busch S, Moritz A, Erbel R, et al. Association of a human G-protein beta3 subunit variant with hypertension. Nat Genet 1998; 18:45-48.
6. Beige J, Hohenbleicher H, Distler A, Sharma AM. G-Protein beta3 subunit C825T variant and ambulatory blood pressure in essential hypertension. Hypertension 1999; 33:1049-1051.
7. Benjafield AV, Jeyasingam CL, Nyholt DR, Griffiths LR, Morris BJ. G-protein beta3 subunit gene (GNB3) variant in causation of essential hypertension. Hypertension 1998; 32:1094-1097.
8. Brand E,Wang JG, Herrmann SM, Staessen JA. An epidemiological study of blood pressure and metabolic phenotypes in relation to the Gbeta3 C825T polymorphism. J Hypertens 2003; 21:729-737.
9. Hengstenberg C, Schunkert H, Mayer B, Doring A, Lowel H, Hense HW, et al. Association between a polymorphism in the G protein beta3 subunit gene (GNB3) with arterial hypertension but not with myocardial infarction. Cardiovasc Res 2001; 49:820-827.
10. Schunkert H, Hense HW, Doring A, Riegger GA, Siffert W. Association between a polymorphism in the G protein beta3 subunit gene and lower renin and elevated diastolic blood pressure levels. Hypertension 1998; 32:510-513.
11. Bagos PG, Elefsinioti AL, Nikolopoulos GK, Hamodrakas SJ. The GNB3 C825T polymorphism and essential hypertension: a meta-analysis of 34 studies including 14,094 cases and 17,760 controls. J Hypertens 2007; 25:487-500.
12. Pollex RL, Hanley AJ, Zinman B, Harris SB, Khan HM, Hegele RA. Metabolic syndrome in aboriginal Canadians: prevalence and genetic associations. Atherosclerosis 2006; 184:121-129.
13. Yamamoto M, Abe M, Jin JJ, Wu Z, Tabara Y, Mogi M, et al. Association of GNB3 gene with pulse pressure and clustering of risk factors for cardiovascular disease in Japanese. Biochem Biophys Res Commun 2004; 316:744-748.
14. Wascher TC, Paulweber B, Malaimare L, Stadlmayr A, Iglseder B, Schmoelzer I, et al. Associations of a human G protein beta3 subunit dimorphism with insulin resistance and carotid atherosclerosis. Stroke 2003; 34:605-609.
15. Pollex RL, Hanley AJ, Zinman B, Harris SB, Hegele RA. Clinical and genetic associations with hypertriglyceridemic waist in a Canadian aboriginal population. Int J Obes (Lond) 2006; 30:484-491.
16. Ishikawa K, Imai Y, Katsuya T, Ohkubo T, Tsuji I, Nagai K, et al. Human Gprotein beta3 subunit variant is associated with serum potassium and total cholesterol levels but not with blood pressure. Am J Hypertens 2000; 13:140-145.
17. Saller B, Nemesszeghy P, Mann K, Siffert W, Rosskopf D. Glucose and lipid metabolism in young lean normotensive males with the G protein beta3 825T-allele. Eur J Med Res 2003; 8:91-97.
18. Suwazono Y, Kobayashi E, Uetani M, Miura K, Morikawa Y, Ishizaki M, et al. G-protein beta 3 subunit polymorphism C1429T and low-density lipoprotein receptor-related protein 5 polymorphism A1330V are risk factors for hypercholesterolemia in Japanese males: a prospective study over 5 years. Metabolism 2006; 55:751-757.
19. von Beckerath N, Schusterschitz Y, Koch W, Griesser K, Mehilli J, Gorchakova O, et al. G protein beta 3 subunit 825T allele carriage and risk of coronary artery disease. Atherosclerosis 2003; 167:135-139.
20. Nurnberger J, Opazo Saez A, Mitchell A, Buhrmann S, Wenzel RR, Siffert W, et al. The T-allele of the C825T polymorphism is associated with higher arterial stiffness in young healthy males. J Hum Hypertens 2004; 18:267-271.
21. Hanon O, Luong V, Mourad JJ, Bortolotto LA, Safar M, Girerd X. Association between the G protein beta3 subunit 825t allele and radial artery hypertrophy. J Vasc Res 2002; 39:497-503.
22. von Beckerath N, Kastrati A, Koch W, Bottiger C, Mehilli J, Seyfarth M, et al. G protein beta3 subunit polymorphism and risk of thrombosis and restenosis following coronary stent placement. Atherosclerosis 2000; 149:151-155.
23. Morrison AC, Doris PA, Folsom AR, Nieto FJ, Boerwinkle E. G-protein beta3 subunit and alpha-adducin polymorphisms and risk of subclinical and clinical stroke. Stroke 2001; 32:822-829.
24. Naber CK, Husing J,Wolfhard U, Erbel R, SiffertW. Interaction of the ACE D allele and the GNB3 825T allele in myocardial infarction. Hypertension 2000; 36:986-989.
25. Yamada Y, Izawa H, Ichihara S, Takatsu F, Ishihara H, Hirayama H, et al. Prediction of the risk of myocardial infarction from polymorphisms in candidate genes. N Engl J Med 2002; 347:1916-1923.
26. Renner W, Hoffmann MM, Grunbacher G, Winkelmann BR, Boehm BO, Marz W. G-protein beta3 subunit (GNB3) gene polymorphisms and cardiovascular disease: the Ludwigshafen Risk and Cardiovascular Health (LURIC) study. Atherosclerosis 2007; 192:108-112.
27. Nurnberger J, Dammer S, Mitchell A, Siffert W, Wenzel RR, Gossl M, et al. Effect of the C825T polymorphism of the G protein beta 3 subunit on the systolic blood pressure-lowering effect of clonidine in young, healthy male subjects. Clin Pharmacol Ther 2003; 74:53-60.
28. Filigheddu F, Reid JE, Troffa C, PinnaParpaglia P, Argiolas G, Testa A, et al. Genetic polymorphisms of the beta-adrenergic system: association with essential hypertension and response to beta-blockade. Pharmacogenomics J 2004; 4:154-160.
29. Turner ST, Schwartz GL, Chapman AB, Boerwinkle E. C825T polymorphism of the G protein beta(3)-subunit and antihypertensive response to a thiazide diuretic. Hypertension 2001; 37 (2 Part 2):739-743.
30. Nicholson AC, Hajjar DP. Transforming growth factor-beta up-regulates low density lipoprotein receptor-mediated cholesterol metabolism in vascular smooth muscle cells. J Biol Chem 1992; 267:25982-25987.
31. Khoury MJ, Flanders WD. Nontraditional epidemiologic approaches in the analysis of gene-environment interaction: case-control studies with no controls! Am J Epidemiol 1996; 144:207-213.
32. Young JH, Chang YP, Kim JD, Chretien JP, Klag MJ, Levine MA, et al. Differential susceptibility to hypertension is due to selection during the outof-Africa expansion. PLoS Genetics 2005; 1:e82.
33. Hayakawa T, Takamura T, Abe T, Kaneko S. Association of the C825T polymorphism of the G-protein beta3 subunit gene with hypertension, obesity, hyperlipidemia, insulin resistance, diabetes, diabetic complications, and diabetic therapies among Japanese. Metabolism 2007; 56:44-48.
34. Vijayagopal P, Srinivasan SR, Radhakrishnamurthy B, Berenson GS. Studies on the mechanism of uptake of low density lipoprotein-proteoglycan complex in macrophages. Biochim Biophys Acta 1991; 1092:291-297.
35. Virchow S, Ansorge N, Rosskopf D, Rubben H, Siffert W. The G protein beta3 subunit splice variant Gbeta3-s causes enhanced chemotaxis of human neutrophils in response to interleukin-8. Naunyn Schmiedebergs Arch Pharmacol 1999; 360:27-32.
36. Chang PY, Luo S, Jiang T, Lee YT, Lu SC, Henry PD, et al. Oxidized low-density lipoprotein downregulates endothelial basic fibroblast growth factor through a pertussis toxin-sensitive G-protein pathway: mediator role of platelet-activating factor-like phospholipids. Circulation 2001; 104:588-593.
37. Naber C, Hermann BL, Vietzke D, Altmann C, Haude M, Mann K, et al. Enhanced epinephrine-induced platelet aggregation in individuals carrying the G protein beta3 subunit 825T allele. FEBS Letters 2000; 484:199-201.
38. Davignon J. Beneficial cardiovascular pleiotropic effects of statins. Circulation 2004; 109 (23 Suppl 1):III39-III43.
39. Takemoto M, Liao JK. Pleiotropic effects of 3-hydroxy-3-methylglutaryl coenzyme a reductase inhibitors. Arterioscler Thromb Vasc Biol 2001; 21:1712-1719.
40. Zhang J, Yu KF. What's the relative risk? A method of correcting the odds ratio in cohort studies of common outcomes. J Am Med Assoc 1998; 280:1690-1691.